ESTRO 2025 - Abstract Book

S2097

Clinical - Urology

ESTRO 2025

Tiziana Burla 1 , Giulia Marvaso 2,3 , Sofia Netti 4 , Sara Gandini 4 , Mattia Zaffaroni 2 , Maria Giulia Vincini 2 , Chiara Lorubbio 2 , Cristiana Iuliana Fodor 2 , Dario Zerini 2 , Stefano Luzzago 5 , Francesco Alessandro Mistretta 5 , Ketti Mazzocco 1 , Giuseppe Petralia 6 , Gabriella Pravettoni 1,3 , Gennaro Musi 5,3 , Ottavio De Cobelli 5,3 , Barbara Alicja Jereczek-Fossa 2,3 1 Division of Applied Research for Cognitive and Psychological Sciences, IEO European Institute of Oncology IRCCS, Milan, Italy. 2 Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. 3 Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. 4 Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. 5 Division of Urology, IEO European Institute of Oncology IRCCS, Milan, Italy. 6 Division of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy Purpose/Objective: Prostate cancer (PCa) diagnosis and treatment may have a significant impact on patients’ quality of life (QoL), with physical, emotional, and social effects. Considering the lengthening of post-intervention survival, a deeper comprehension of the treatment's effect on QoL may have an important role in personalizing interventions with better long-term outcomes. One of the secondary endpoints of the RADIOSA phase II randomized clinical trial (NCT03940235) aimed to evaluate the QoL of treated oligoreccurent PCa patients, comparing the effects of SBRT alone vs SBRT with a short course ADT. Material/Methods: Patients with up to 3 bone or lymph node lesions were enrolled and randomly assigned to two different arms: SBRT-alone (ARM A) and SBRT + 6 months ADT (ARM B). Participants filled out three validated questionnaires within 2 weeks prior to randomization (T0), at 3 (T1) and 12 months, and yearly thereafter: (i) the University of California Los Angeles (UCLA) Prostate Cancer Index, (ii) the SF-36 measures health; (iii) the Impact of Events scale (IES-R). Wilcoxon tests and chi-square test were run to compare QoL changes over 3 months (from T0 and T1) between the two arms. A minimal clinical important difference (MCID) was defined based on available literature 1 . Mixed models with repeated measures were used to assess QoL trend over time in interaction with the type of treatment. Results: 97 participants (46 ARM A and 51 ARM B) were considered for the current analysis. Statistically significant differences in the QoL after 3 months were found for the Urinary Function (UCLA-UF, p =0.042), Sexual Function (UCLA-SF, p = 0.004), Physical Functioning (SF36-PF, p =0.021) and Social Functioning (SF36-SF, p =0.016) scales, with lower scores in ARM B than in ARM A. The only MCID at three months was found for sexual functioning with a worsening in the arm B ( Figure 1 ). Preliminary results from mixed models with repeated measures suggest that the trend of worsening on Physical Functioning (SF36-PF) may last also at 1-year FU. No other significant interactions were found.